A team of researchers from the United Kingdom and the United States recently completed the first large-scale trial of a low-cost, multi-active pill that reduces the risk of angina and stroke, and the results have been promising as predicted by experts 18 years ago.
In 2001, researchers proposed the production of a low-cost, multi-active pill to prevent cardiovascular disease. The pill contains several drugs, including aspirin, to reduce the risk of angina and stroke.
In the trial, published in the Lancet honorary journal, the experts combined aspirin, atorvastatin to reduce fat, and enalapril and hydrochlorothiazide to lower the pressure in a pill that is expected to cost a few cents. They tested the bean on at least 6841 participants aged at least 55 years in 236 Iranian villages.
The researchers noted that the pill reduced the risk of developing cardiovascular disease by 34%, but this proportion fell to 22% when patients take other cardiac drugs, in addition to the new pill.
The Panel hopes that the study will demonstrate the long-awaited promise of the pill. "The use of this simple, static dosage formulation for the prevention of cardiovascular disease has been much discussed, and our experiments have shown its effectiveness," said researcher Tom Marshall So Guardian.